Back to search results
NCT02092155

Biomarker Levels During Indwelling Pleural cAtheter Sample Testing

Enrolling by Invitation
Not specifiedAges 18–99Observational
Johns Hopkins University
~95 participants
Updated 2025-12-17 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To determine the median time to pleurodesis
Measured over 12 week follow up

Conditions

Malignant Pleural Effusions

Explore related trials

Malignant Pleural Effusion

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Lonny Yarmus, DO · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pleural effusion (etiology fulfilling one of the following criteria):
18 years of age
Symptoms such as shortness of breath, cough, or chest fullness/chest discomfort
Demonstration of symptomatic improvement after therapeutic thoracentesis
Recurrent pleural effusion after therapeutic thoracentesis
Capacity to provide informed consent

Exclusion

Projected life expectancy less than 30 days.
Radiographic evidence of trapped lung - persistent lung collapse with failure of the majority (\>50%) of the lung to reexpand following drainage of a pleural effusion
Previous lobectomy or pneumonectomy on the affected side
Patient receiving intrapleural chemotherapy
Chylothorax - pleural effusion with triglyceride levels \> 110 mg/dl or chylomicrons on lipoprotein analysis, most commonly due to trauma/obstruction of the thoracic duct
Parapneumonic effusion - pleural effusion associated with pneumonia
Empyema - infected pleural space as defined by purulent pleural fluid, positive gram stain, or positive culture
Inability to adequately perform pleural drainage at home
Uncorrectable bleeding disorder
Skin infection at the site of intended catheter insertion
Pregnant women - detected by spot urine testing prior to the procedure

What this trial measures

  • To determine the median time to pleurodesis12 week follow up

    Duration of follow-up will be 12 weeks. After 12 weeks, all patients who do not achieve spontaneous pleurodesis will adhere to the standard drainage protocol.